Drugs and Generics

Opana ER Delayed Generics Antitrust Settlement

Impax Laboratories, Inc. is settling its part of an antitrust class action about an alleged conspiracy between itself and a group of Endo companies, including Endo Health Solutions, Inc., Endo Pharmaceuticals, Inc., and Penwest Pharmaceuticals Co. The complaint alleged that, in June 2010, Impax and Endo entered into a “pay for delay” agreement delaying the  Read more

Bristol-Myers Squibb HIV cART Drugs Antitrust Direct Purchaser Partial Settlement

This is a partial settlement of an antitrust class action against Bristol-Myers Squibb Company, ER Squibb & Sons, LLC, and others. The complaints alleged that the companies violated antitrust laws by conspiring to extend patent protection for antiretroviral drugs for treating human immunodeficiency virus (HIV cART drugs) by engaging in anticompetitive conduct and restraining competition,  Read more

Ranbaxy TPP Generic Nexium, Diovan, and Valcyte Settlement

Sun Pharmaceutical Industries, Ltd. and Ranbaxy, Inc. are settling combined class actions alleging generic drug manufacturer Ranbaxy made misrepresentations about both the conditions in its plants and the results of analyses on the integrity of data at the plants. This allowed it to obtain “tentative approval” from the Food and Drug Administration (FDA) and a  Read more

Bystolic Drug Companies Noncompete Agreements Antitrust Class Action

When it’s time for a “blockbuster” drug’s patent to expire, makers of generics are normally in a hurry to create their own versions. However, the complaint for this antitrust class action alleges that those involved with the drug Bystolic entered into noncompete agreements with potential competitors, to delay the entry of generics into the market.  Read more

Pfizer, Ranbaxy Lipitor Generic Anticompetitive Agreement Class Action

With the high prices of US drugs, a popular medicine can be an enormous moneymaker for a pharmaceutical company. But the patents that give those companies exclusivity have a limited term, after which generics or bioequivalents can come on the market, driving prices downwards. The complaint for this antitrust class action alleges that a number  Read more

Forest Laboratories Namenda Alzheimer’s Drug Antitrust Class Action

This antitrust class action alleges that Forest Laboratories, LLC attempted to retain its monopoly on its $1.5 billion-per-year drug, Namenda IR by preventing less expensive generics from coming to market. Namenda IR is prescribed to treat moderate to severe dementia in Alzheimer’s patients. It was approved by the Food and Drug Administration (FDA) in 2003.  Read more

Lovenox/Enoxaparin Antitrust Settlement

Momenta Pharmaceuticals, Inc. and Sandoz, Inc. are settling an antitrust class action alleging that they conspired to keep the prices of Lovenox and its generic enoxaparin higher than they should have been by manipulating the generic approvals process. While Momenta did not create the drug, the complaint says the companies manipulated the process to bring  Read more

Glumetza Diabetes Drug Antitrust Conspiracy Class Action

What’s a fair price for a thirty-day supply of the extended-release diabetes medicine Glumetza—generic name metformin? Is it $55 or $2,200? The complaint for this class action alleges that a number of companies conspired to limit the entry of generic versions of Glumetza to the market. The defendants in this antitrust suit are Bausch Health  Read more

Provigil, Nuvigil, Modafinil Antitrust Settlements

An antitrust class action and an antitrust case brought by the California Attorney General (CAAG) on the same topic are being settled at the same time. The suits claim that drug companies conspired to keep prices of the original drug Provigil high by delaying the introduction of generics and (in the CAAG suit) of Nuvigil.  Read more

Ranbaxy Misled FDA to Get First-to-File Rights to Generics Class Action

The complaint for this class action alleges that Ranbaxy Laboratories, Ltd. took advantage of Food and Drug Administration (FDA) rules on approvals for generic drugs. The complaint says it claimed first-to-file rights for generics of popular drugs even when it had not yet sufficiently developed the generics, in order to block others from doing so.  Read more